PLAT and ischemic stroke: Tissue-type plasminogen activator (tPA) is the only FDA-approved drug for ischemic stroke, but its use is finite due to the narrow therapeutic time window (within 3 h or 4.5 h) and the increased risk of severe neurovascular complications, such as hemorrhagic transformation (HT) and edema [2], resulting in the fact that more than 95% of stroke patients cannot benefit from thrombolytic therapy [3].